低剂量CT联合血清P16甲基化检测在肺癌早期诊断中的研究

Study of low-dose computed tomography and serum P16 gene methylation measurement serum for early diagnosis of lung cancer

目的 研究在无症状的肺癌高危人群中低剂量CT（LDCT）联合血清P16基因甲基化检测对肺癌早期诊断的可行性。方法 405例受试者随机分入LDCT＋P16甲基化检测组（221例）和前后位胸片（CXR）组（184例）。入选标准为：男性，55～75岁，吸烟指数≥200年支。结果 LDCT＋P16甲基化组97．7％（216例）和CXR组93．5％（173例）的受试者完成检测。LDCT＋P16甲基化组与CXR组分别有22例（10．2％）和13例（7．5％）可疑肺癌，3例及1例确诊肺癌。结论 LDCT联合P16基因甲基化检测比CXR检查发现更多的肺癌。

Objective To determine the feasibility of conducting low-dose computed tomography （LDCT） and serum P16 gene methylation measurement for early diagnosis of lung cancers in symptomatic individuals at high risk of lung cancer. Methods 4-05 patients were randomly divided into two groups： LDCT ＋ P16 gene methylation measurement group（221 cases）and posterio-anterior view chest X-ray （CXR） examination group（ 184 cases）. Inclusion criteria was de- fined as male measurement, aged from 55 to 75, smoking over 200 cigarettes per year. Results The experiment was completed in 97. 7% （216 patients） of the LDCT ＋ P16 group, and in 93.5% （ 173 patients） of the CXR group. 22 patients （ 10. 2% ） in the LDCT ＋ P16 group and 13 patients（7.5% ） in the CXR group were suspicious for lung cancer. A total of 3 cases of lung cancer in the LDCT ＋ P16 group and 1 case in the CXR group were diagnosed. Conclusions More lung cancer cases can be detected through LDCT plus P16 gene methylation measurement than CXR.